Latest / Decera Clinical Education Oncology Podcast
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include:
Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancer
Factors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expression
Determining the need for adjuvant chemotherapy and selection of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.